Log in   

Login to your account

Kim Bergström, Ph.D.

NanoSPECT/CT In Vivo Imaging

Group Leader

Kim Bergström received his Ph.D. in Radiochemistry in 1995 (University of Kuopio, Finland). Since 2010 Dr. Bergström has served as Group Leader and Adjunct Professor at the CDR. During 2007-2010, he served as CEO of Imanext Ltd, a CRO company specializing in molecular imaging. During 2006-2007 he was acting Head of Radiopharmaceutical Research at University of Helsinki. He worked as R&D; Director at MAP Medical Technologies Oy (subsidiary of Schering AG) during 2001-2005, where he earned significant experience in clinical development. Prior to this he served as Vice Chief Chemist at Kuopio University Hospital for more than 10 years, researching and developing molecular imaging tracers and methods.

Dr. Bergström has obtained international research experience as a post-doctoral fellow (Dept. of Neuropsychiatric Research, Karolinska Hospital, Stockholm) in 1995-1996. Dr. Bergström was awarded a degree in Biotechnology Management from the Helsinki School of Business Administration in 2003.
Dr. Bergström’s publication list consists of more than 100 peer reviewed scientific publications in the field of radiochemistry, radiopharmacy and nuclear medicine.
Kim Bergström has received the following scientific awards:

  • Timo Heiskanen Prize, Finnish Society of Nuclear Medicine and FinnishSociety of Radiology (2001)
  • CIS Jean Debiesse Award “Nuclear Medicine”, European Association of Nuclear Medicine (1995)

He has served as a member of the editorial boards of Current Radiopharmaceuticals and the European Journal of Nuclear Medicine. He has served as a member of the management boards of three EU COST projects as well as Principal Investigator of a EU EUREKA project. He has been a reviewer of numerous journals, theses, and licentiate theses, and has been opponent of two theses in Finland and one in Sweden.

Dr. Bergström heads the NanoSPECT/CT In Vivo Imaging Group at CDR. This platform enables real-time morphological imaging and tracking of radiolabeled substances in rodents at ultra-high resolution ( 0.5 mm), quantitatively, and in 3D. It is suitable for a variety of research applications in oncology, neurology, cardiovascular pharmacology, target discovery, and gene expression studies; and, also for pharmacodynamic, pharmacokinetic, and morphological measurements. For information regarding fee-based contract imaging services or for industrial/academic collaborations, please contact CDR.


Current Group Members

Fields marked with * are required

From the Director

You must have the Adobe Flash Player installed to view this player.

Recent Activities